Vifor Pharma inks $340m deal with Angion Biomedica Inc.
Swiss drugmaker Vifor Pharma has licenced US and EU commercialisation rights of Angion Biomedica’s experimental kidney drug ANG-3777.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
DASbox® Mini Bioreactor System
Most Compact System for Early Stage Processes – The Eppendorf DASbox Mini Bioreactor System, with its small working volume, compact design, as well as advanced control and information management options is ideal for research and early development processes.
Richter-Helm, the CDMO matching your needs
CDMO Continuous growth and diversification of the biotechnology market for pharmaceutical production have been recorded in the past years. It is expected that both trends, growth and diversification from blockbusters towards niche products, will continue. What requirements are derived from customers’ point of view and what are the advantages of Richter-Helm as a successful CDMO to fulfil such needs?
What’s in a patent?
IP – In a recent decision (Royalty vs. DPMA; C-650/17), the European Court of Justice (ECJ) has shed some light on the conditions under which a supplementary protection certificate (SPC) may be granted. It has thus ended discussions that had arisen following earlier somewhat elusive ECJ-decisions. Whether this will be the last word to be heard on the topic remains to be seen.
Cell and gene therapy specialist Minaris expanding
Japanese CDMO Minaris Regenerative Medicine Co. Ltd will invest US$64.5m to expand its facilities in Europe and Asia.
Protein Brewery raise €22m in Series A
Lead investor Novo Growth has led a €22m Series A investment in The Protein Brewery, a Dutch company that is to supplement the market for protein alternatives by fungal protein.
Best of Biotech made in Germany
Growing sector – growing guide: The 22nd edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Galecto raise US$85m in Nasdaq IPO
HBM portfolio company Galecto has raised US$85m through the placement of 5.67 million new shares at a price of US$15 per share at Nasdaq.
BI initiates Phase II testing of COVID-19 drug
Boehringer Ingelheim announced the start of Phase II studies of its oral TRPC6 blocker code-named BI 764198 in patients hospitalised for COVID-19.
AP-Protector® – Diluent for long-term storage of AP conjugates
AP-Protector® is a long-term stabilizer for alkaline phosphatase (AP) coupled to antibodies or Neutravidin/Streptavidin.